Name of Student Nurse: ____PASCUAL, BRYAN T.

_______ Date: ____Nov 1, 2021_______

Level/Block/Group: _3BSN-08__ Hospital/Area: ___________ Clinical Instructor:,

NAME OF DRUG MECHANISM OF CONTRAINDICATI SIDE EFFECTS ADVERSE NURSING

ACTION ONS EFFECTS RESPONSIBILITIES
GENERIC NAME Hypersensitivity to CNS: headache,

Directl Hypert
 Assess for change
oxytocin. insomnia, weakness
in severity of HIV
Cephalopelvic symptoms and for
lopinavir,
ritonavir
BRAND NAME
y
disproportion
Fetal intolerance of
labor
CV: Torsades De
Pointes, ↑ PR
onicity symptoms of
opportunistic

may
Anticipated non interval, heart block, infections during

Kaletra affects vaginal

deliver
QT interval
prolongation

therapy.
Assess patient for

CLASSIFICATIO neurore
 Hypersensitivity
(including toxic Derm: ERYTHEM
occur signs of
pancreatitis
N epidermal A
with (nausea, vomiting,

ceptor necrolysis,
Stevens-Johnson
MULTIFORME, ST
EVENS JOHNSON
abdominal pain,
increased serum
syndrome, or
SYNDROME, TOX
tearing lipase or amylase)

sites to
Antiretrovirals IC EPIDERMAL
erythema NECROLYSIS, periodically during
multiforme); RASH
of therapy. May

stimulat
 Concurrent use require

uterus,
of alfuzosin, discontinuation of
Endo: hyperglycemi
colchicine, a therapy.

e
INDICATION dihydroergotami  Assess patient for
ne, dronedarone,
elbasvir/grazopr GI: HEPATOTOXI increas rash (mild to
moderate rash
HIV infection (with
other
antiretrovirals).
contract evir, ergotamine,
lomitapide,
CITY, PANCREAT
ITIS, diarrhea,
abdominal pain, ed usually occurs in
the 2nd week of

ion of
lovastatin, nausea, taste, therapy and
lurasidone,
methylergonovi
vomiting.
bleedi resolves within 1–
2 week of
DOSAGE &
FREQUENCY the ne, midazolam
(PO), pimozide,
ranolazone,
Misc: immune
reconstitution
ng, continued
therapy). If rash is
severe (extensive

uterus abrupti
PO (Adults): syndrome
sildenafil erythematous or
Patients with <3
(Revatio), maculopapular
lopinavir
resistance-
associated during
simvastatin, and
triazolam (may on rash with moist
desquamation or
substitutions– 400/
placent
result in serious angioedema) or

labor
100 mg (two and/or life- accompanied by
200/50-mg tablets
or 5 mL oral threatening systemic
solution) twice
daily  or  800/200
especial 
events);
Concurrent use ae symptoms (serum
sickness-like
mg (four 200/50-mg
Fetal
with St. John's reaction, Stevens-
tablets or 10 mL

ly
oral solution) once wort or rifampin Johnson
daily;   Hypersensitivity syndrome, toxic
or intolerance to
bradyc epidermal

Patients with ≥3
lopinavir
toward alcohol or castor
oil
ardia
necrolysis),
therapy must be
 Congenital long discontinued
resistance-
associated
substitutions– 400/
the end QT syndrome,
concurrent use
Low
immediately.

of
100 mg (two of QT-interval

Apgar
200/50-mg tablets prolonging Lab Test Considerations:
or 5 mL oral
solution) twice drugs, or  Monitor viral
daily; 
the 
hypokalemia
OB:  Not score
load and CD4
counts regularly
during therapy.
recommended in
Pregnant women
with no lopinavir
resistance-
pregnan pregnancy if ≥1
lopinavir at 5
 Monitor
triglyceride and
cholesterol
resistance-
associated

cy, min,
associated levels prior to
substitutions– 400/
substitution initiating
100 mg (two
200/50-mg tablets) present; therapy and
twice daily;
helping  Lactation: Brea
st feeding not
recommended in
Prolon 
periodically
during therapy.
May cause
PO (Children  14
days–6 mo): Oral
solution– 16/4
expel HIV-infected
patients; ged IV 
hyperglycemia.
Monitor liver

the
Pedi:  Preterm function before
infusio
mg/kg
lopinavir/ritonavir infants (should and during
content twice daily. be avoided until therapy,

baby. It n of
14 days after
PO (Children  ≥6 especially in
their due date)
mo and <15 or full-term patients with
kg): Oral

oxytoc
infants <14 days underlying
solution– 12/3
mg/kg
lopinavir/ritonavir
also old hepatic disease,
including
twice daily.
PO (Children  ≥6 contract in with hepatitis B and
hepatitis C, or
mo and 15–40
kg): Oral
solution– 10/2.5 s excessi marked
transaminase
elevations. May
mg/kg
ve cause ↑ serum

myoepi
lopinavir/ritonavir
twice daily. AST, ALT,

PO (Children  ≥6
fluid GGT, and total

thelial
mo): Tablets– 15– bilirubin
concentrations.
volum
25 kg: 200/50 mg
(two 100/25-mg  Monitor serum
tablets) twice daily;
26–35 kg: 300/75
mg (three 100/25-
cells in e has
lipase and
amylase levels
during therapy.
mg tablets) twice
daily; >35 kg:
400/100 mg (four
the caused
 Monitor blood
glucose during

breasts,
100/25-mg tablets therapy. May
or two 200/50-mg
tablets) twice daily severe cause
hyperglycemia.

causing water
milk to intoxic
be ation
express with
ed from seizure
the s,
coma,
alveoli
death
into the  Diarrhea
 Hyperlipidemia

ducts so 

Nausea
Abdominal

that the 
pain
ALT increased

baby 

Elevated LFTs
Hyperuricemia

can 

Flatulence
Neutropenia

obtain  Stevens
 Johnson

it 
Syndrome
Erythema

by 
multiforme
Toxic

sucklin epidermal
necrolysis

g.
Directl
y
affects
neurore
ceptor
sites to
stimulat
e
contract
ion of
the
uterus
during
labor
especial
ly
toward
the end
of
the
pregnan
cy,
helping
expel
the
baby. It
also
contract
s
myoepi
thelial
cells in
the
breasts,
causing
milk to
be
express
ed from
the
alveoli
into the
ducts so
that the
baby
can
obtain
it
 by
sucklin
g.
Protease Inhibitor;
inhibits cleavage of Gag-
Pol polyprotein

Reference:

https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/51453/all/lopinavir_ritonavir#5